<?xml version="1.0" encoding="UTF-8"?>
<p>Despite evidence demonstrating that CINV control is optimized when guideline recommendations are followed [
 <xref rid="mdx698-B5" ref-type="bibr">5</xref>, 
 <xref rid="mdx698-B6" ref-type="bibr">6</xref>], guidelines are often inadequately adhered to in clinical practice. This may, in part, be due to perceived complexity of some of the multimodal antiemetic regimens, as the NK
 <sub>1</sub>RAs, 5-HT
 <sub>3</sub>RAs, and corticosteroid components each have differing doses/schedules from 1 to 4â€‰days post-chemotherapy initiation. Simpler, less frequent dosing regimens have been shown to result in better compliance across a variety of therapeutic classes [
 <xref rid="mdx698-B10" ref-type="bibr">10</xref>]. 
</p>
